Kohner E M, Pettit J E, Hamilton A M, Bulpitt C J, Dollery C T
Br Med J. 1976 Mar 6;1(6009):550-3. doi: 10.1136/bmj.1.6009.550.
Forty patients with central retinal vein occlusion were allocated at random either to a treatment group given streptokinase followed by anticoagulatns or to a control group given no specific treatment. The two groups, which were each of 20 patients, were broadly similar in respect of clinical and laboratory values and similar in their initial visual acuity. At follow-up ("final" vision) the visual acuity in the treated group was significantly better than in the untreated group. Only one treated patient developed thrombotic glaucoma compared with four controls. Streptokinase may, however, have been responsible for vitreous haemorrhage (and permanent loss of vision) in three patients and hence probably has only a limited role in the treatment of central retinal vein occlusion.
40例视网膜中央静脉阻塞患者被随机分为两组，一组为治疗组，接受链激酶治疗后再给予抗凝剂；另一组为对照组，不接受特殊治疗。两组各有20例患者，在临床和实验室指标方面大致相似，初始视力也相似。随访时（“最终”视力），治疗组的视力明显优于未治疗组。治疗组仅有1例患者发生血栓性青光眼，而对照组有4例。然而，链激酶可能导致了3例患者发生玻璃体积血（以及永久性视力丧失），因此它在视网膜中央静脉阻塞的治疗中可能仅起有限的作用。
